NCT06383598 PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors
| NCT ID | NCT06383598 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hua Zhu |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-04-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To utilize the \[68Ga\]Ga-THP-PDL1-3 molecular probe to non-invasively detect PD-L1 expression in primary and metastatic lesions of patients with solid tumors. Furthermore, to assess the heterogeneity of PD-L1 expression within the same lesion and across different lesions, and to observe changes in PD-L1 expression during the course of treatment. This approach aims to facilitate patient screening, therapeutic monitoring, and early warning of drug resistance and/or recurrence or metastasis in the treatment of solid tumors with high PD-L1 expression, ultimately enabling personalized targeted therapy in oncology.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-70 years, ECOG score 0 or 1; 2. Patients with solid tumors; 3. Presence of measurable lesions on imaging examinations; 4. Expected survival ≥12 weeks. Exclusion Criteria: 1. Severe hepatic or renal dysfunction; 2. Women who are planning pregnancy, pregnant, or breastfeeding; 3. Unable to remain in supine position for 30 minutes; 4. Refusal to participate in this clinical study; 5. Diagnosis of claustrophobia or other psychiatric disorders; 6. Other conditions deemed by the investigator as inappropriate for participation in the trial.
Contact & Investigator
Hua Zhu
PRINCIPAL INVESTIGATOR
Peking University Cancer Hospital & Institute
Frequently Asked Questions
Who can join the NCT06383598 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06383598 currently recruiting?
Yes, NCT06383598 is actively recruiting participants. Contact the research team at zhuhuabch@pku.edu.cn for enrollment information.
Where is the NCT06383598 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06383598 clinical trial?
NCT06383598 is sponsored by Hua Zhu. The principal investigator is Hua Zhu at Peking University Cancer Hospital & Institute. The trial plans to enroll 50 participants.